Related Experiment Video
Updated: Dec 30, 2025
Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
Published on: April 2, 2021
Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis
Thierry Gustot1,2,3,4,5, Rob Ter Heine6, Elisa Brauns1
1Department of Gastroenterology and Hepato-Pancreatology, CUB Erasme, Brussels, Belgium.
Insights
Caspofungin dosage adjustments for cirrhosis are debated. This study suggests maintaining the full caspofungin dose in patients with cirrhosis to ensure effective drug exposure and avoid subtherapeutic levels.
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Clinical Pharmacology
- Infectious Diseases
Background:
- Current guidelines recommend reducing caspofungin dosage in patients with Child-Pugh (CP) B or C cirrhosis.
- This recommendation is based on concerns about altered drug metabolism in hepatic impairment.
Purpose of the Study:
- To evaluate the impact of cirrhosis severity on caspofungin pharmacokinetics (PK).
- To determine appropriate caspofungin dosing strategies for cirrhotic patients.
Main Methods:
- Pharmacokinetic studies of caspofungin in patients with CP-B and CP-C cirrhosis.
- Analysis of drug exposure with a 35 mg dose compared to standard dosing.
- Monte Carlo simulations to assess steady-state drug concentrations.
Main Results:
- Caspofungin clearance showed only a marginal reduction in patients with cirrhosis.
- A reduced dose of 35 mg resulted in lower drug exposure compared to standard doses in non-cirrhotic patients.
- Simulations indicated potential subtherapeutic levels with dose reduction.
Conclusions:
- The study recommends administering the full dose of caspofungin irrespective of cirrhosis presence or severity.
- Avoiding dose reduction is crucial to prevent subtherapeutic drug exposure in cirrhotic patients.
- Clinical practice may need to deviate from current product information regarding caspofungin dosing in cirrhosis.
Background:
Controversies remain over caspofungin dosage adjustments in cirrhosis, particularly Child-Pugh (CP) B or C. The product information for of caspofungin recommends a maintenance dose reduction from 50 to 35 mg for patients with CP-B cirrhosis.
Objectives:
To quantify the impact of cirrhosis and the severity of hepatic impairment on the pharmacokinetics (PK) of caspofungin.
Patients And Methods:
We performed PK studies of a single 70 mg dose of caspofungin in patients with decompensated CP-B (n = 10) or CP-C (n = 10) cirrhosis and of multiple doses in 21 non-cirrhotic ICU patients with hypoalbuminaemia. A Monte Carlo simulation was performed to investigate the impact of a maintenance dose reduction from 50 to 35 mg on the steady-state area under the 24 h concentration-time curve.
Results:
We observed a marginal reduction of caspofungin clearance in a PK study in patients with decompensated CP-B or CP-C cirrhosis. Dose reduction to 35 mg in cirrhotic patients resulted in lower drug exposure than with the approved dose in non-cirrhotic patients.
Conclusions:
In contrast to the product information, we recommend giving the full dose of caspofungin regardless of the presence and severity of cirrhosis to avoid a subtherapeutic exposure.
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...